DNMT3B and Miyoshi myopathy: Additionally, we show that DNMT3B supports MM cell growth and survival, by sustaining cell cycle progression and stemness-related transcriptional programs and stabilizing MYC protein, and DNMT3B targeting displays strong anti-MM activity, sensitizing the MM cells to several SoC agents.